Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Sequence specific reagents targeting CCR5 in primary hematopoietic cells

Sequence specific reagents targeting CCR5 in primary hematopoietic cells

US Patent 11767512 · Granted Sep 26, 2023

Estimated economic value: $673,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Modified Cas9 system having a dominant negative effector on non-homologous end-j2025
Modified Cas9 system having a dominant negative effector on non-homologous end-j2025
Modified Cas9 system having a dominant negative effector on non-homologous end-j2025
Chimeric antigen receptors that bind to prostate specific membrane antigen2025
Targeted gene insertion for improved immune cells therapy2025
Method for improving production of car T cells2025
Method for generating t-cells compatible for allogenic transplantation2025
Targeted gene integration of CRS inhibitor genes for improved immune cells thera2025
Targeted gene integration of NK inhibitors genes for improved immune cells thera2025
Cellular immunotherapy for repetitive administration2024
Biodegradable multilayer nanocapsules for the delivery of biologically active ag2024
Biodegradable multilayer nanocapsules for the delivery of biologically active ag2024